1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 4: 
Intra-arterial chemotherapy for retinoblastoma in infants weighing ≤10 kg (74 treated eyes with 222 IAC sessions)—clinical outcomes
VariableWeight ≤10 kg (n = 74 Eyes; 35.7% of 69 Patients)Weight >10 kg (n = 133 Eyes; 64.2% of 127 Patients)P ValueTotal (n = 207) Eyes (%) of 196 Patients
Complete tumor regression57 (82.6)81 (60.9).02138 (66.6)
Globe enucleation16 (21.6)52 (39.1).0168 (32.8)
Follow-up duration (months) (n = 196), mean (median, range)31.7 (22.7, 1.7–157.2)30.0 (23.4, 0.2–112.4).7330.6 (22.8, 0.2–157.2)